Skip to main content
OpenTrials
Completed

NCT Number: NCT04704518

Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy

Phase IV comparative, controlled, parallel group, open, randomized multicenter study to evaluate the efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo. Primary outcome measure is the time of corneal re-epithelialization after PRK surgery. Intervention includes administration of one of the experimental products quater per die (QID) for 14 days.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Photorefractive Keratectomy Corneal De-epithelialization

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Aris Vision Institute de Guadalajara, S. C.

Guadalajara, Jalisco, Mexico

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Age ≥ 18 and ≤ 45 years old
  • Being on PRK postoperative day 1 (right eye will be evaluated for efficacy)
  • Presenting a PRK surgical corneal ablation surface of 5.5 to 6.0 mm
  • PRK corneal output ≤ 60 µm
  • Preoperative refraction of -1.0 to -4.5 D of myopia or myopic astigmatism (in this case, the sum of both values with a spherical equivalent no greater than -4.5 D)
  • Being capable of voluntarily grant a signed informed consent.
  • Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
  • Being willing and able to modify the required lifestyle activities.
  • Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study.

Exclusion criteria

  • Having suffered any complications during and after PRK surgical procedure previous to inclusion in the study.
  • Use of mitomycin during PRK
  • Being subjected to PRK retreatment of previous history of any other kind of refractive surgery.
  • Pregnancy, breastfeeding or planning to become pregnant during the time of the study
  • Having participated in clinical trials within 30 days prior to signing this study's informed consent form.
  • Having participated previously in this study.
  • Diagnosis of any of the following:
  • Allergic, viral or bacterial conjunctivitis
  • Dry eye
  • Anterior blepharitis
  • Parasite infestation of ocular structures (Demodex, for example)
  • Previous history of ocular herpes
  • Previous history of ocular inflammation (such as uveitis)
  • Corneal or conjunctival ulcers
  • Glaucoma
  • Previous history of drug addiction within the last 2 years previous to signing this study's informed consent form.
  • Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
  • Previous history of any medical affliction, acute or chronic (such as Diabetes Mellitus type I/II, autoimmune diseases or HIV), that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Use of medications (such as retinoic acid) that according to the investigator's criteria may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Known hypersensitivity to any of the components of the products used in this study.

Treatment and study plan

Sodium Hyaluronate Ophthalmic 0.4%

Drug

Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.

Other names: Lagricel® Ofteno PF, PRO-037

Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%

Drug

Topical ophthalmic administration of one drop of Thealoz® Duo QID.

Other names: Thealoz® Duo

Primary outcomes

  1. Changes in Corneal Re-epithelialization (Time)

    Time frame: Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit)

    Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.

  2. Best Corrected Visual Acuity (BCVA)

    Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

    (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

Secondary outcomes

  1. Changes in Ocular Comfort Index

    Time frame: Days: 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

    Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.

  2. Pain Perception

    Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

    Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4)

  3. Frequency of Pain Perception

    Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)

    Through a questionnaire, patients will be directly questioned about presence, severity and frequency of pain and associated symptoms. The scale will be as follows for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).

  4. Unexpected Adverse Events (AEs) Related to the Investigational Product

    Time frame: Day: 17 (± 1) (safety call)

    The number of unexpected adverse events related to the investigational product that were recorded in each treatment group is described

Sponsors and collaborators

Lead sponsor

Laboratorios Sophia S.A de C.V.

Industry

Registry information

Official study title

Phase IV Clinical Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo for Corneal Re-epithelialization After Photorefractive Keratectomy (PRK)

Acronym: PRO-037

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jan 11, 2021
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.